Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T-cells.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Cancer Research

• Publication date

  1992-01-15

• Fields of study

  Medicine

• Identifiers
  PMID 1728411
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer

  2004cited by this paper
• MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele.

  1991cited by this paper
• Treatment of human melanoma hepatic metastases in nude mice with human cytotoxic T lymphocytes.

  1991cited by this paper
• Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas.

  1990influential reference
• Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.

  1990cited by this paper
• Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes.

  1990cited by this paper
• Inhibition of the growth of human melanoma xenografts in nude mice by human tumor‐specific cytotoxic T‐cells

  1990cited by this paper
• Antitumor activity and surface phenotypes of human glioma-infiltrating lymphocytes after in vitro expansion in the presence of interleukin 2.

  1989cited by this paper
• Functional and phenotypic analysis of tumor‐infiltrating. Lymphocytes isolated from human primary and metastatic. Liver tumors and cultured in recombinant interleukin‐2

  1989cited by this paper
• Generation of autologous tumor-specific cytotoxic T-cells using HLA-A region matched allogeneic melanoma.

  1989cited by this paper
• The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.

  1989cited by this paper
• Development of antitumor reactivity in regional draining lymph nodes from tumor-immunized and tumor-bearing murine hosts.

  1989cited by this paper
• Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy.

  1989influential reference
• Human cytotoxic T cells specific for autologous melanoma cells: successful generation from lymph node cells in seven consecutive cases.

  1988cited by this paper
• Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. Culture requirements and characterization of immunologic specificity.

  1988cited by this paper
• Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors.

  1988cited by this paper
• Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

  1988cited by this paper
• Phenotype of syngeneic tumor-specific cytotoxic T-lymphocytes and requirements for their in vitro generation from tumor-bearing host and immune spleens.

  1988cited by this paper
• Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.

  1988influential reference
• Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.

  1988cited by this paper
• Autologous lymph node cell‐derived tumor‐specific cytotoxic t‐cells for use in adoptive immunotherapy of human melanoma

  1988influential reference
• A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

  1987influential reference
• In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.

  1987cited by this paper
• Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.

  1987cited by this paper
• Human T cells specifically activated against autologous malignant melanoma.

  1987cited by this paper
• Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.

  1987cited by this paper
• Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

  1987cited by this paper
• High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings.

  1986cited by this paper
• Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.

  1986cited by this paper
• A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2.

  1986cited by this paper
• Functional characterization of T lymphocytes propagated from human lung carcinomas.

  1986cited by this paper
• In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells.

  1986cited by this paper
• A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

  1986influential reference
• Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

  1985cited by this paper
• Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2

  1984influential reference
• Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

  1984cited by this paper
• Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

  1982cited by this paper
• Proceedings of the third International Workshop on Nude Mice

  1982cited by this paper

• Structure-Guided T Cell Receptor Mutations that Alter Antigen Specificity, Cross-Reactivity, and Polyfunctional Phenotypes in Gene-Modified T Cells

  2019cites this paper
• Immunomodulatory activity of glycodelin: implications in allograft rejection

  2018cites this paper
• Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma

  2018cites this paper
• The metastasis of hepatocarcinoma can be inhibited by T lymphocytes reconstitution in nude mice model.

  2010cites this paper
• Human reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient

  2008cites this paper
• Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model

  2007cites this paper
• Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy

  2005cites this paper
• Melanoma-Associated Antigens in Esophageal Adenocarcinoma

  2004cites this paper
• Human Telomerase Reverse Transcriptase-Transduced Human Cytotoxic T Cells Suppress the Growth of Human Melanoma in Immunodeficient Mice

  2004cites this paper
• Melanoma-associated antigens in esophageal adenocarcinoma: identification of novel MAGE-A10 splice variants.

  2004cites this paper
• Adoptive transfer of an anti‐MART‐127–35‐specific CD8+ T cell clone leads to immunoselection of human melanoma antigen‐loss variants in SCID mice

  2003cites this paper
• ALLOGENIC VACCINE AND METHOD TO SYNTHESIZE SAME-European Patent Office-EP 0684831 B1

  2003cites this paper
• Immunotherapy of Malignant Melanoma in a SCID Mouse Model Using the Highly Cytotoxic Natural Killer Cell Line NK-92

  1999cites this paper
• Vaccination of Melanoma Patients with Interleukin 4 Gene-Transduced Allogeneic Melanoma Cells

  1999cites this paper
• Characterization of Genetically Altered, Interleukin 2-Independent Natural Killer Cell Lines Suitable for Adoptive Cellular Immunotherapy

  1999cites this paper
• Cells and cytokines in immunotherapy and gene therapy of cancer.

  1999cites this paper
• Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice.

  1998cites this paper
• In vivo eradication of an established human melanoma by an in vitro generated autologous cytotoxic T cell clone: A SCID use model

  1998cites this paper
• One Hundred Years of Cancer Immunotherapy: A Critical Appraisal

  1997cites this paper
• Adoptive transfer of cytotoxic T lymphocytes induced by CD86-transfected tumor cells suppresses multi-organ metastases of C1300 neuroblastoma in mice

  1997cites this paper
• Immunomodulating Antitumor Mechanisms of SMANCS

  1997cites this paper
• Antisense therapy for B cell lymphomas.

  1997cites this paper
• Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV- induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice [published erratum appears in J Exp Med 1996 Sep 1;184(3):1199]

  1996cites this paper
• Limited Antitumor T Cell Response in Melanoma Patients Vaccinated with Interleukin-2 Gene-Transduced Allogeneic Melanoma Cells

  1996cites this paper
• Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer.

  1996cites this paper
• HLA-B-Restricted, CD8+ Cytolytic Human T Cell Clones Derived from a Melanoma-Invaded Lymph Node

  1996cites this paper
• Antibody-targeted lymphokine-activated killer cells inhibit liver micrometastases in severe combined immunodeficient mice.

  1995cites this paper
• A phase I trial of B7-transfected or parental lethally irradiated allogeneic melanoma cell lines to induce cell-mediated immunity against tumor-associated antigen presented by HLA-A2 or HLA-A1 in patients with stage IV melanoma. NCI protocol T93-0161. BRMP protocol 9401.

  1995cites this paper
• A Phase I Trial of B7-Transfected or Parental Lethally Irradiated Allogeneic Melanoma Cell Lines to Induce Cell-Mediated Immunity Against Tumor-Associated Antigen Presented by HLA-A2 or HLA-A1 in Patients with Stage IV Melanoma. National Institutes of Health, Bethesda, Maryland

  1995cites this paper
• Immunotherapy of Human Melanoma With Gene-Modified Tumor Cell Vaccines.

  1995cites this paper
• Induction of tumor-specific cytotoxic T lymphocytes by tumor necrosis factor-α (TNF α) in cancer patients

  1995cites this paper
• Enhancement of tumor-specific cytotoxic T lymphocyte activity in cancer patients by pretreatment with cyclophosphamide

  1994cites this paper
• Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells.

  1994cites this paper
• Retroviral vector-mediated cytokine-gene transfer into tumor cells.

  1993cites this paper
• Production and regulation of gelatinase B by human T-cells.

  1993cites this paper
• Effects of anti-transforming growth factor-beta antibody and interleukin-2 in tumor-bearing mice.

  1993cites this paper
• Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in SCID/hu mice.

  1993influential citation
• Possibilities of immunotherapy and gene therapy for malignant melanoma.

  1993cites this paper
• Effects of Anti-transforming Growth Factor-β Antibody and Interleukin-2 in Tumor-bearing Mice

  1993cites this paper
• Relationship between disease-free interval and survival in patients with recurrent melanoma.

  1992cites this paper
• Cancer immunotherapy: are the results discouraging? Can they be improved?

  1992cites this paper
• Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-gamma in irradiated human melanoma cells.

  1992cites this paper